India, May 22 -- ImmunityBio, Inc. (IBRX) shares declined 6.65 percent to $7.22, down $0.51 on Friday, despite the company presenting new patient survey findings related to bladder cancer treatment preferences at ISPOR 2026.
The stock is currently trading at $7.22, compared with a previous close of $7.74 on the Nasdaq. It opened at $7.64 and traded between $7.17 and $7.69 during the session, with volume reaching 6.78 million shares, below the average daily volume of 22.81 million shares.
ImmunityBio Inc. released data from a mixed-methods study conducted with Fight Bladder Cancer examining treatment priorities among patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer.
googletag.cmd.push(functi...